E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with Multiple Sclerosis |
Pazienti con Sclerosi Multipla |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Hormonal diseases [C19] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10022891 |
E.1.2 | Term | Investigations |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10014698 |
E.1.2 | Term | Endocrine disorders |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the prevalence of GHD and/ or IGF-I deficiency in patients with multiple sclerosis |
Valutare la prevalenza del GHD e/o il deficit di IGF-1 in pazienti con sclerosi multipla prima e dopo terapia a lungo termine con Interferone beta (IFN beta). |
|
E.2.2 | Secondary objectives of the trial |
Correlate the prevalence of GH and/or IGF-I deficit with the Index of disability and the Multiple Sclerosis Severity Score |
Correlare l'eventuale deficit di GH e/o IGF-I con l'Indice di disabilita' e punteggio di severita' per la sclerosi multipla |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients aged 30-50 yrs with Multiple sclerosis and never treated
Written informed consent to participate into the study. |
Pazienti con diagnosi di SM che non siano stati precendemente trattati con terapia immunomodulatoriae di eta' compresa tra 30-50 anni, al fine di evitare l'interferenza eta'-dipendente che porta al declino dell'asse GH-IGF-
Consenso informato scritto a partecipare allo studio. |
|
E.4 | Principal exclusion criteria |
No exclusion criteria |
Non vi sono criteri di esclusione |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To investigate the prevalence of GHD and/ or IGF-I deficiency in patients with multiple sclerosis |
Valutare la prevalenza del GHD e/o il deficit di IGF-1 in pazienti con sclerosi multipla prima e dopo terapia a lungo termine con Interferone beta (IFN beta). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |